Eton Pharmaceuticals, Inc. — FY 2020 Form 10-K
Reporting period: Year ended December 31, 2020. The company is a specialty pharmaceutical business developing, acquiring and commercializing products, with a focus on hospital injectables and pediatric and rare-disease treatments. Its financial statements were audited and presented fairly in accordance with U.S. GAAP; the auditor did not opine on internal-control effectiveness.
Financial performance and position
Amounts below are in millions of dollars except per-share data. The filing reports limited commercial revenue as the company expanded its product development and commercial operations.
| Metric | 2020 | 2019 |
|---|---|---|
| Net revenue | $0.039 | $0.959 |
| Cost of product sales | $0.286 | $0.453 |
| Gross profit (loss) | $(0.247) | $0.506 |
| Research and development | $14.104 | $11.555 |
| General and administrative | $12.760 | $7.552 |
| Operating loss | $(27.111) | $(18.601) |
| Net loss | $(27.970) | $(18.320) |
| Net loss per share, basic and diluted | $(1.33) | $(1.03) |
| Net cash used in operating activities | $(22.346) | $(18.026) |
- Revenue fell sharply year over year: 2020 included only a limited contribution from Alkindi Sprinkle, launched in December. The 2019 comparison included a $0.5 million licensing milestone for EM-100 and initial Biorphen sales.
- Gross loss in 2020 reflected Biorphen price discounts to wholesalers and a $0.623 million reserve for slow-moving inventory considered at risk of expiring unsold. Biorphen’s 2019 gross profit benefited from different timing and product-launch activity.
- Operating expenses rose $7.757 million, with higher R&D spending and a $5.208 million increase in G&A, primarily from added personnel, launch-related sales and marketing, and legal costs tied to the Cysteine patent challenge.
- At year-end, cash and cash equivalents were $21.295 million, working capital was $20.9 million, total current assets were $24.701 million and current liabilities were $3.794 million. Total assets were $26.319 million.
- Year-end debt included $6.532 million of long-term SWK debt, net of discount, plus $0.511 million of PPP and EIDL loans. The SWK facility is secured by company assets, has a stated 10% interest rate plus a LIBOR floor, and requires a minimum $3 million cash balance. The company reported $0.797 million of interest paid in 2020.
- Cash increased $9.229 million during 2020, principally reflecting $31.625 million of financing cash flow, including common-stock offerings and borrowing; operating activities used $22.346 million. Cash used in investing was $0.050 million.
Business developments and comparison with prior period
- The company reported nine products or candidates submitted to FDA and three FDA-approved products. Alkindi Sprinkle was approved in September 2020 and launched in December as a pediatric adrenal-insufficiency replacement therapy. It is protected by four issued patents extending to 2034.
- Biorphen, an FDA-approved ready-to-use phenylephrine injection, launched in December 2019. Eton reported difficulty building hospital demand during 2020 as COVID-19 disrupted in-person promotion. Alaway Preservative Free was approved in 2020; Bausch Health launched it in February 2021 under a royalty arrangement.
- In February 2021, Eton sold its three pediatric neurology candidates—zonisamide, topiramate and lamotrigine—to Azurity. The transaction provides for up to $45 million: $15 million at closing, $15 million tied to FDA approval and launch milestones, and $15 million tied to sales milestones, plus a single-digit royalty on net sales. Eton received $9.5 million in February; $5.5 million of the closing payment was held in escrow pending product-related milestones.
- Other candidates approaching FDA decisions included dehydrated alcohol injection (PDUFA date May 27, 2021), ephedrine ready-to-use injection (June 18, 2021), zonisamide (May 29, 2021) and topiramate (August 6, 2021). Lamotrigine had received a Complete Response Letter in March 2020; FDA requested revised dosing information and a human-factors validation study.
- Management said year-end cash, product revenues and the $9.5 million received from the Azurity sale were expected to fund operations for at least 12 months from the financial-statement issuance date, subject to assumptions about sales and spending. The filing cautions that faster spending or slower product growth could require earlier financing or operating reductions.
Outlook, risks and unusual items
- Management plans to grow sales of approved products, pursue additional late-stage orphan-drug opportunities and use partner-led commercialization and royalties for certain products. No specific revenue, earnings or cash-flow guidance was provided.
- COVID-19 affected Biorphen promotion and could disrupt clinical work, FDA timelines, manufacturing and future commercial activity. The company also cited uncertainty around product adoption, pricing and reimbursement, competition, regulatory approvals, intellectual-property rights and reliance on third-party manufacturers and partners.
- Cysteine development faces ongoing Paragraph IV patent litigation, which Eton expected could delay final FDA approval beyond tentative approval. The filing also identifies related-party arrangements and potential conflicts, including a CEO interest in a counterparty connected with EM-100.
- The company had an accumulated deficit of $92.158 million and no income-tax expense; it maintained a full valuation allowance against $17.903 million of deferred tax assets. Management noted possible limits on the use of tax-loss carryforwards after ownership changes.
- The audit identified estimated product-sales deductions—returns, chargebacks, discounts and fees—as a critical audit matter because sales history was limited and the estimates involved subjective assumptions. The auditor’s opinion on the financial statements was unmodified.
Important facts for investors to verify
- Whether Alkindi Sprinkle and Biorphen sales improve, and whether Biorphen inventory reserves, returns and wholesale discounts stabilize.
- FDA decisions, timing and any required additional work for dehydrated alcohol, ephedrine, zonisamide, topiramate and lamotrigine.
- Receipt and release conditions for Azurity’s escrowed $5.5 million, and the likelihood and timing of the remaining milestone and royalty payments.
- Liquidity runway against continued operating cash use, debt service and SWK covenants; assess potential need for additional financing and dilution.
- Outcome and financial exposure from Cysteine-related litigation, along with material changes in related-party arrangements or intellectual-property rights.